marketcap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Zynex EBITDA 2011-2025 | ZYXI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.89 M | 13.5 M | 25.1 M | 24.6 M | 11.8 M | 11.8 M | 10.8 M | 9.23 M | 1.08 M | -2.06 M | -5.04 M | -6.76 M | 3.65 M | 3.91 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.1 M | -6.76 M | 7.9 M |
Quarterly EBITDA Zynex
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -12.5 M | - | - | - | 1.16 M | - | - | - | 899 K | - | 8.15 M | 4.36 M | 2.41 M | 11.6 M | 9.74 M | 3.81 M | -594 K | 2.3 M | 2.45 M | 4.62 M | 2.71 M | 3.73 M | 3.04 M | 2.72 M | 2.42 M | 2.88 M | 2.82 M | 2.72 M | 1.98 M | 3.59 M | 3.04 M | 1.93 M | 583 K | 518 K | 722 K | -150 K | -350 K | - | -226 K | -363 K | -772 K | - | 412 K | -5.42 M | -1.15 M | - | -460 K | -2.15 M | -149 K | - | 1.36 M | 1.36 M | 699 K | - | 1.7 M | 1.29 M | 54 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | -12.5 M | 1.54 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Dynatronics Corporation
DYNT
|
-1.97 M | $ 0.24 | 14.99 % | $ 929 K |  USA |
 |
Aziyo Biologics
AZYO
|
-26.8 M | $ 1.48 | 1.37 % | $ 20.5 M | USA |
 |
Natus Medical Incorporated
NTUS
|
51.9 M | $ 31.08 | 1.94 % | $ 1.05 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | $ 3.05 | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | $ 20.0 | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | $ 30.03 | - | $ 111 M |  Canada |
 |
Apollo Endosurgery
APEN
|
-30.2 M | $ 10.0 | - | $ 475 M | USA |
 |
Titan Medical
TMDI
|
-31 M | $ 0.14 | -26.32 % | $ 19.6 M | Canada |
 |
Viveve Medical
VIVE
|
-20.4 M | $ 0.22 | -15.35 % | $ 1.71 M | USA |
 |
Invacare Corporation
IVC
|
-65 M | $ 0.66 | - | $ 24.7 M | USA |
 |
Abiomed
ABMD
|
254 M | $ 381.02 | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | $ 0.55 | 3.58 % | $ 2.21 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | $ 17.84 | -4.14 % | $ 702 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | $ 24.04 | - | $ 1.77 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | $ 20.12 | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | $ 10.38 | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | $ 30.65 | 0.03 % | $ 1.58 B |  Israel |
 |
FONAR Corporation
FONR
|
9.84 M | $ 14.9 | 1.02 % | $ 97.7 M | USA |
 |
Misonix, Inc.
MSON
|
-15.9 M | $ 26.54 | - | $ 462 M | USA |
 |
ShockWave Medical
SWAV
|
169 M | $ 334.75 | - | $ 12.3 B | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
-47 M | $ 7.16 | 0.28 % | $ 270 M | USA |
 |
ViewRay
VRAY
|
-102 M | $ 2.64 | 1.54 % | $ 468 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | $ 28.24 | - | $ 955 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 39.01 | -2.96 % | $ 5.81 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | $ 70.98 | - | $ 3.31 B | USA |
 |
Integer Holdings Corporation
ITGR
|
319 M | $ 66.65 | -2.19 % | $ 2.24 B | USA |
 |
BIOLASE
BIOL
|
-15.1 M | $ 0.13 | -13.19 % | $ 166 K | USA |
 |
Eargo
EAR
|
-106 M | $ 2.57 | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
-12.3 M | $ 8.57 | -1.27 % | $ 244 M | USA |
 |
SmileDirectClub
SDC
|
-188 M | $ 0.08 | -53.45 % | $ 9.71 M | USA |
 |
Globus Medical
GMED
|
420 M | $ 61.13 | -0.62 % | $ 8.3 B | USA |
 |
ThermoGenesis Holdings
THMO
|
-5.27 M | $ 0.31 | -25.84 % | $ 171 K | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | $ 0.09 | -26.83 % | $ 2.62 M | USA |
 |
ClearPoint Neuro
CLPT
|
-18.8 M | $ 18.43 | 8.54 % | $ 498 M | USA |
 |
Surgalign Holdings
SRGA
|
-76.3 M | $ 0.18 | -32.98 % | $ 1.68 M | USA |
 |
Conformis
CFMS
|
-42.2 M | $ 2.27 | - | $ 16.4 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-15.9 M | $ 16.33 | -0.24 % | $ 377 M | USA |
 |
Sientra
SIEN
|
-42 M | $ 0.18 | -16.59 % | $ 10.3 M | USA |
 |
NuVasive
NUVA
|
147 M | $ 39.75 | - | $ 2.07 B | USA |
 |
Cutera
CUTR
|
-148 M | $ 0.1 | -10.19 % | $ 1.99 M | USA |
 |
Nemaura Medical
NMRD
|
-9.15 M | $ 0.11 | -17.8 % | $ 2.74 M |  Britain |
 |
Medtronic PLC
MDT
|
8.82 B | $ 90.21 | -0.21 % | $ 116 B | USA |
 |
Vapotherm
VAPO
|
-34.1 M | $ 1.27 | 6.72 % | $ 34 M | USA |
 |
Pulmonx Corporation
LUNG
|
-56.6 M | $ 1.76 | 3.24 % | $ 68.8 M | USA |
 |
Myomo
MYO
|
-10.5 M | $ 0.85 | -2.04 % | $ 5.99 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
-66 M | $ 4.38 | 3.55 % | $ 7.96 M | USA |
 |
Alphatec Holdings
ATEC
|
-57.8 M | $ 19.34 | -1.93 % | $ 2.76 B | USA |
 |
Inari Medical
NARI
|
-23.4 M | $ 79.97 | - | $ 4.23 B | USA |